TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyEva Nievergall, Deborah L. White, Samantha J. Busfield et al.|Leukemia|2016Cited by 50
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinibChung Hoow Kok, Timothy P. Hughes, David T Yeung et al.|Blood Advances|2019Cited by 43